OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant.
The outer surface protein A (OspA) lipoprotein of Borrelia burgdorferi, like cholera toxin and the heat-labile enterotoxin of Escherichia coli, induces pro-inflammatory cytokines. This suggested that, like those toxins, OspA might be a mucosal immunogen and adjuvant. OspA, administered intranasally (i.n.) or intragastrically, induced strong serum IgG and salivary gland IgA responses. The serum IgG isotypes were indicative of a mixed T helper 1 and T helper 2 response, the latter being more pronounced. The N-terminal tripalmitoyl-S-glyceryl-cysteine (Pam3Cys) lipid moiety was absolutely required. OspA strongly enhanced the serum IgG and salivary gland IgA responses to jack bean urease co-administered by the i.n. route. OspA also enhanced the response to tetanus toxoid and induced limited protection against challenge. A synthetic lipopeptide also adjuvanted the response to urease by the i.n. route, but was ca 500-fold less potent on a molar basis than OspA. These results suggest that OspA or other lipoproteins may be useful in mucosal vaccines.
Erdile
L F
LF
Pasteur Mérieux Connaught, Marcy L'Etoile, France.
Guy
B
B
D000276:Adjuvants, Immunologic / Q000737:chemistry*; D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000097:blood / Q000276:immunology; D000954:Antigens, Surface / Q000008:administration & dosage / Q000276:immunology*; D001425:Bacterial Outer Membrane Proteins / Q000008:administration & dosage / Q000276:immunology*; D001428:Bacterial Vaccines; D015748:Borrelia burgdorferi Group / Q000276:immunology*; D005260:Female; D018928:Immunity, Mucosal / Q000276:immunology*; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000097:blood / Q000276:immunology; D007156:Immunologic Memory / Q000276:immunology; D007441:Intubation, Gastrointestinal; D008055:Lipids / Q000276:immunology; D008074:Lipoproteins / Q000008:administration & dosage / Q000138:chemical synthesis / Q000276:immunology*; D008193:Lyme Disease / Q000517:prevention & control; D051379:Mice; D008809:Mice, Inbred C3H; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology; D012469:Salivary Glands / Q000276:immunology / Q000378:metabolism; D013745:Tetanus Toxoid / Q000276:immunology; D014510:Urease / Q000008:administration & dosage / Q000276:immunology
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D007074:Immunoglobulin G; D008055:Lipids; D008074:Lipoproteins; C072045:OspA protein; D011994:Recombinant Proteins; D013745:Tetanus Toxoid; D014510:Urease